Dallas脂肪变指数在UK Biobank人群中预测非酒精性脂肪性肝病的验证
该研究基于UK Biobank人群验证Dallas脂肪变指数(DSI)对非酒精性脂肪性肝病(NAFLD)的预测效能。NAFLD影响全球四分之一人口,但 specialty society guidelines 不推荐在一般人群筛查NAFLD,部分因成本效益未证实。
要点
- NAFLD影响全球约四分之一人口,是公共卫生危机。
- 指南不推荐一般人群筛查NAFLD,成本效益尚未证实。
- DSI在UK Biobank中验证用于预测NAFLD。
核心结论
- NAFLD是全球公共卫生危机,影响世界四分之一人口。
- 通过减重和消除肝脂肪变预防心脏代谢或肝脏并发症是初级保健中NAFLD筛查项目的核心目标。
- 专业学会指南不推荐在一般人群筛查NAFLD,部分因成本效益未证实。
主要发现
- NAFLD影响全球四分之一人口。
- 专业学会指南不推荐在一般人群筛查NAFLD。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Nonalcoholic fatty liver disease (NAFLD) is a global public health crisis that affects one quarter of the world population.1 Preventing either cardiometabolic or liver-related complications by achieving weight loss and resolving hepatic steatosis would be the central goal of a NAFLD screening program in the primary care setting. Despite the overwhelming prevalence and the multimodal impact on health posed by NAFLD, specialty society guidelines do not recommend screening for NAFLD in the general population,2 partly owing to the as-yet unproven cost benefit.
引用
- McHenry S, Park Y, Davidson NO, et al. Validation of the Dallas Steatosis Index to Predict Nonalcoholic Fatty Liver Disease in the UK Biobank Population. Clin Gastroenterol Hepatol. 2021. PMID: 34044131. doi:10.1016/j.cgh.2021.05.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。